These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19748281)

  • 21. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
    Tuffaha HW; Treish IM; Zaru L
    J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.
    Rajan SS; Lyman GH; Stearns SC; Carpenter WR
    Med Care; 2011 Jul; 49(7):649-57. PubMed ID: 21478779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
    Waladkhani AR
    Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
    Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
    Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
    Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.
    Rivera E; Erder MH; Moore TD; Shiftan TL; Knight CA; Fridman M; Brannan C; Danel-Moore L; Hortobagyi GN;
    Cancer; 2003 Jul; 98(2):222-8. PubMed ID: 12872339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
    Ozer H; Mirtsching B; Rader M; Luedke S; Noga SJ; Ding B; Dreiling L
    Oncologist; 2007 Apr; 12(4):484-94. PubMed ID: 17470691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
    Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
    Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.
    Ng R; Green MD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):585-90. PubMed ID: 16111460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients.
    Chan A; Leng XZ; Chiang JY; Tao M; Quek R; Tay K; Lim ST
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):75-81. PubMed ID: 21332654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer.
    Waller CF; Semiglazov VF; Tjulandin S; Bentsion D; Chan S; Challand R
    Onkologie; 2010; 33(10):504-11. PubMed ID: 20926897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
    Martino M; Praticò G; Messina G; Irrera G; Massara E; Messina G; Console G; Iacopino P
    Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
    Crawford J
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):22-8. PubMed ID: 16736985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of toxicity and toxicity profile of adjuvant chemotherapy in elderly breast cancer patients.
    Garg P; Rana F; Gupta R; Buzaianu EM; Guthrie TH
    Breast J; 2009; 15(4):404-8. PubMed ID: 19508671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
    Jagasia MH; Greer JP; Morgan DS; Mineishi S; Kassim AA; Ruffner KL; Chen H; Schuening FG
    Bone Marrow Transplant; 2005 Jun; 35(12):1165-9. PubMed ID: 15880129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.
    Staber PB; Holub R; Linkesch W; Schmidt H; Neumeister P
    Bone Marrow Transplant; 2005 May; 35(9):889-93. PubMed ID: 15765110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims.
    Weycker D; Hanau A; Lonshteyn A; Bowers C; Garawin T; Bensink M; Chandler D
    Curr Med Res Opin; 2019 Apr; 35(4):725-730. PubMed ID: 30182756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.